

Mesothelioma Workshop

A workshop hosted by the NCRI Clinical Studies Groups in association with the British Lung Foundation and Department of Health



Naim Dangoor Auditorium, Royal Society of Medicine

1 Wimpole Street, London

2nd May 2014 09.30 – 17.00

09.30 – 10.00 Registration and light refreshments

10.00 – 10:05 Welcome - Introduction to the workshop

Dr Marianne Nicolson, Aberdeen Royal Infirmary; NCRI Lung CSG Chair

10:05 – 10:20 Current funded research in mesothelioma and current funding opportunities

Mr Ian Jarrold, British Lung Foundation & Dr Marianne Nicolson, Aberdeen Royal Infirmary

10:20 – 12:45 Session 1: Harnessing current resources in mesothelioma research

Chair: Dr Peter Szlosarek, Barts Cancer Institute, Queen Mary University

10:20 – 10:40 Mesothelioma research and funding within the UK

Professor Anne Willis & Professor Marion MacFarlane, Medical Research Council

10:40 – 11:00 The genetic landscape of mesothelioma

Dr Peter Campbell, Wellcome Trust Sanger Institute

11.00 – 11:20 Coffee break

11:20 – 11:50 Key Note: Anti-mesothelin immunotoxin therapy for malignant mesothelioma

Dr Raffit Hassan, National Cancer Institute

11:50 – 12:10 Pre-clinical platforms for identifying new drugs

Dr Ultan McDermott, Wellcome Trust Sanger Institute

12:10 – 12:25 Novel agents in mesothelioma

Professor Dean Fennell, University of Leicester; NCRI Mesothelioma Subgroup Chair

12:25 – 12:45 Panel discussion

12.45 – 13:35 Lunch – Max Rayne Foyer and ENT room

13:35 – 14:40 Session 2: Priority setting and funding success

Chair: Mr John Edwards, Sheffield Thoracic Institute, University of Sheffield

13:35 – 13:50 MesoBank

Dr Robert Rintoul, Cambridge Cancer Centre; NCRI Screening and Early Diagnosis (lung) Chair

13:50 – 14:10 European research links with the UK - Mesoscape

Professor Paul Baas, Netherlands Cancer Institute

14:10 – 14:20 Update of the James Lind Alliance priorities

Mr Ian Jarrold, British Lung Foundation

14:20 – 14:40 Panel discussion

14:40 – 17:00 Session 3: Concept generation - breakout groups (Further information overleaf)

Chair: Dr Robert Rintoul, Cambridge Cancer Centre

14:40 – 16:00 Breakout Groups - Potential studies, trials & concepts:

A) 'Tissue collection & Logistics' - Chair: Dr Robert Rintoul, Cambridge Cancer Centre

B) 'Basic Science & Genomics' – Chairs: Dr Peter Campbell & Dr Ultan McDermott, Wellcome Trust Sanger Institute.

C) 'Translational & Clinical Questions A' - Chairs: Professor Dean Fennell, University of Leicester & Mr John Edwards, Sheffield Thoracic Institute, University of Sheffield

D) 'Translational & Clinical Questions B' - Chairs: Dr Marianne Nicolson Aberdeen Royal Infirmary & Chair: Dr Peter Szlosarek, Barts Cancer Institute

16:00 – 16:45 Feedback from breakout groups - please return to **Naim Dangoor Auditorium**

10 minutes per breakout group and 5 minutes of questions & discussion

16:45 – 17:00 Summary of the day: **Next steps and closing remarks**

Dr Marianne Nicolson, Aberdeen Royal Infirmary; NCRI Lung CSG Chair